Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma — Ann‐Lii Cheng (2021) | RDL Network
Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Zhen Xu, Sairy Hernandez, Juan Liu, Hui Shao, Huang Chen, Ann-LII Cheng, Richard S. Finn, Peter R. Galle
Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla, Yulei Wang, Ho Yeong Lim, Andrew X. Zhu, Ann‐Lii Cheng
Discussion(0)
No comments yet. Be the first to comment.